• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vera Therapeutics Inc Cl A (NQ: VERA )

    41.99 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 41.99
    Bid (Size) 16.89 (1)
    Ask (Size) 66.76 (1)
    Prev. Close 41.99
    Today's Range 41.99 - 41.99
    52wk Range 9.240 - 50.78
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
    From Vera Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +168.99%
    +168.99%
    1 Month
    +4.43%
    +4.43%
    3 Month
    +17.75%
    +17.75%
    6 Month
    -2.05%
    -2.05%
    1 Year
    +156.19%
    +156.19%

    More News

    Read More
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Vera Therapeutics to Participate at September Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vera Therapeutics
    Via GlobeNewswire
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
    From Vera Therapeutics
    Via GlobeNewswire
    VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Could This Stock Be the Next Biotech Buyout?
    Via The Motley Fool
    Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
    Via Benzinga
    Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Via Investor's Business Daily
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.